Induction of paclitaxel resistance by the Kaposi's sarcoma-associated herpesvirus latent protein LANA2.
Kaposi's sarcoma-associated herpesvirus (KSHV) is the causal agent of both KS and primary effusion lymphoma (PEL). Although treatment with paclitaxel has significant antitumor activity in KS, drug resistance represents a major obstacle for improving the overall response and survival of PEL patients. The transcriptional pattern of KSHV is cell/tissue specific, as revealed by the fact that the viral latent protein LANA2 is detected exclusively in B cells. This paper focuses on the mechanism of paclitaxel resistance observed in PEL cells. Here we show that LANA2 protein modulates microtubule dynamics through its direct binding to polymerized microtubules, preventing microtubule stabilization induced by paclitaxel. This is the first demonstration of paclitaxel resistance induced by a viral protein and suggests a link between the expression of LANA2 and the resistance of PEL cells to paclitaxel.
Muñoz-Fontela
C
C
Centro Nacional de Biotecnologia, CSIC, Darwin 3, Campus Universidad Autonoma, Madrid 28049, Spain.
Marcos-Villar
L
L
Hernandez
F
F
Gallego
P
P
Rodriguez
E
E
Arroyo
J
J
Gao
S-J
SJ
Avila
J
J
Rivas
C
C
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002460:Cell Line; D019008:Drug Resistance, Neoplasm; D019288:Herpesvirus 8, Human / Q000502:physiology*; D006801:Humans; D008870:Microtubules / Q000378:metabolism / Q000821:virology; D017239:Paclitaxel / Q000494:pharmacology*; D014764:Viral Proteins / Q000502:physiology*
D000970:Antineoplastic Agents; D014764:Viral Proteins; D017239:Paclitaxel